Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

Saeedi, Pouya; Salpea, Paraskevi; Karuranga, Suvi; Petersohn, Inga; Malanda, Belma; Gregg, Edward W.; Unwin, Nigel; Wild, Sarah H.; Williams, Rhys

doi:10.1016/j.diabres.2020.108086

Cited by 496 publications

(350 citation statements)

References 8 publications

Supporting

Mentioning

329

Contrasting

Unclassified

Order By: Relevance

“…Diabetes is known to be an important cause of excess mortality although the magnitude of this effect is highly variable in different populations with a relative risk of 1.15-3.15 with cardiovascular diseases being consistently observed to be the main cause of this risk [8]. The data on mortality from the 9 th Edition of the IDF Atlas 2019 [9] demonstrate a wide regional variation, which are also likely to reflect differences in the demographics of those with diabetes, the level of public health investment in diabetes care which will be influenced in turn by socio-economic factors including the availability of medicines. Apart from the AFR Region (where the highest death rate is in the age group 30-39 years), all other Regions show a consistent pattern of higher number of deaths due to diabetes in those aged 60 years and older.…”

Section: Discussionmentioning

confidence: 99%

Diabetes and global ageing among 65–99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9th edition

Sinclair

Saeedi

Kaundal

et al. 2020

Diabetes Research and Clinical Practice

Self Cite

315

182

View full text Add to dashboard Cite

The main aims are: (a) to draw attention to the nature and pattern of recent global and regional prevalence estimates and projections of diabetes in older adults (65-99 years), and (b) to describe the societal health implications of these changes on a global scale. Methods: Diabetes prevalences and projections were estimated using a logistic regression method to generate smoothed age-and sex-specific prevalence estimates for 5-year age groups. Results: In 2019, it is estimated that 19.3% of people aged 65-99 years (135.6 million, 95% CI: 107.6-170.6 million) live with diabetes. It is projected that the number of people older than 65 years (65-99 years) with diabetes will reach 195.2 million by 2030 and 276.2 million by 2045. For the regional distribution, the highest prevalence in 2019 being the North America and Caribbean Region at 27.0%. Countries with the highest number of people older than 65 years with diabetes are China, the United States of America and India. Conclusions: There is a need for more data from national and regional sources on those aged 65 years and over, but the prevailing evidence points to diabetes being a considerable global chronic illness burden in ageing societies.

show abstract

Section: Discussionmentioning

confidence: 99%

Diabetes and global ageing among 65–99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9th edition

Sinclair

Saeedi

Kaundal

et al. 2020

Diabetes Research and Clinical Practice

Self Cite

315

182

View full text Add to dashboard Cite

show abstract

“…Diabetes mellitus is a highly prevalent chronic disease characterized by high blood glucose levels and many devastating complications [ 1 , 2 ]. It is estimated to contribute to 11.3% of deaths globally in 2019 [ 3 , 4 ]. According to the International Diabetes Federation Diabetes Atlas, the number of global diabetes cases may reach 578 million in 10 years.…”

Section: Introductionmentioning

confidence: 99%

Astaxanthin Inhibits p70 S6 Kinase 1 Activity to Sensitize Insulin Signaling

Chen

et al. 2020

Marine Drugs

View full text Add to dashboard Cite

Astaxanthin (AST) is a carotenoid with therapeutic values on hyperglycemia and diabetic complications. The mechanisms of action of AST remain incompletely understood. p70 S6 kinase 1 (S6K1) is a serine/threonine kinase that phosphorylates insulin receptor substrate 1 (IRS-1)S1101 and desensitizes the insulin receptor (IR). Our present study aims to determine if AST improves glucose metabolisms by targeting S6K1. Western blot analysis revealed that AST inhibited the phosphorylation of two S6K1 substrates, S6S235/236 and IRS-1S1101, but enhanced the phosphorylation of AKTT308, AKTS473, and S6K1T389 by feedback activation of the phosphatidylinositol-3 (PI-3) kinase in 3T3-L1 adipocytes and L6 myotubes. In vitro kinase assays revealed that AST inhibited S6K1 activity with an IC50 value of approximately 13.8 μM. AST increased insulin-induced IR tyrosine phosphorylation and IRS-1 binding to the p85 subunit of PI-3 kinase. Confocal microscopy revealed that AST increased the translocation of the glucose transporter 4 (GLUT4) to the plasma membrane in L6 cells. Glucose uptake assays using a fluorescent dye, 2-NBDG (2-N-(Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose), revealed that AST increased glucose uptake in 3T3-L1 adipocytes and L6 myotubes under insulin resistance conditions. Our study identifies S6K1 as a previously unrecognized molecular target of AST and provides novel insights into the mechanisms of action of AST on IR sensitization.

show abstract

“…Diabetes mellitus is a public health problem worldwide affecting near half a billion people life, and it has been estimated that the number of people suffering from diabetes will reach 700 million by 2045. 1,2 Type 2 Diabetes Mellitus (T2DM) is a serious and one of the most prevalent metabolic disorders. T2DM is characterized by the inability to control blood glucose due to insulin resistance, inadequate insulin secretion, and excessive or inappropriate glucagon secretion.…”

Section: Introductionmentioning

confidence: 99%

<p>Effect of <em>Rubus anatolicus</em> Leaf Extract on Glucose Metabolism in HepG2, CRI-D2 and C2C12 Cell Lines</p>

Safarzad¹,

Marjani²,

Jazi³

et al. 2020

DMSO

View full text Add to dashboard Cite

The aim of this study was to assess the effects of Rubus anatolicus on glucose metabolism in HepG2, CRI-D2 and C2C12 cell lines. Materials and Methods: R. anatolicus was collected in Golestan province, Iran. Three different cell lines HepG2 (human liver cell), CRI-D2 (mice pancreatic cell) and C2C12 (rat myoblast) were used for cell culture experiments. Cell viability was measured using MTT assay. Cells were treated with various concentrations of the extract (6.25-400 μg/mL) and then the extracellular glucose level and intracellular glycogen content were measured using colorimetric methods. The insulin level of the culture medium was measured using the ELISA method. Results: Our findings showed that R. anatolicus extract enhances glucose uptake and consumption by all three cell lines. The R. anatolicus extract exposure also elevated cellular glycogen content in HepG2 and C2C12 cells (for 200 and 100 μg/mL) significantly. We found a significant increase in glucose uptake and consequently higher stimulation of insulin secretion in CRI-D2 cell pancreatic cells treated with R. anatolicus extract. Conclusion: The R. anatolicus appears to activate glucose uptake and cellular glycogen synthesis probably by activating the glycogenesis or inhibition of glycogenolysis pathways. The extract enhances insulin secretion in the pancreatic cells by increased glucose uptake.

show abstract

Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

Cited by 496 publications

References 8 publications

Diabetes and global ageing among 65–99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9th edition

Diabetes and global ageing among 65–99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9th edition

Astaxanthin Inhibits p70 S6 Kinase 1 Activity to Sensitize Insulin Signaling

<p>Effect of <em>Rubus anatolicus</em> Leaf Extract on Glucose Metabolism in HepG2, CRI-D2 and C2C12 Cell Lines</p>

Contact Info

Product

Resources

About